Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Investor Presentation (August 2025)
17 slides from Oncosil Medical's investor presentation, Aug 7, 2025
Slide 1: ASX Announcement: Release of Investor Webinar Presentation
ASX Announcement 07 August 2025 Release of Investor Webinar Presentation OncoSil Medical Limited (ASX:OSL) (“OSL” or “the Company”) is pleased to release the following investor webinar presentation to the market. The presentation covers both the Company’s achievements over the latter part of its rec
Slide 2: About OncoSil Medical Limited (ASX:OSL)
About OncoSil Medical Limited (ASX:OSL) OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical’s mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32
Slide 3: OSL Update August 2025
For personal use only OSL Update August 2025 Nigel Lange, CEO & Managing Director ASX Code: OSL
Slide 4: Disclaimer
Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil, OSL or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the inf
Slide 5: Executive Summary
Executive Summary • OncoSil Medical is commercialising the OncoSil device, an implanted device (brachytherapy) delivering targeted radiation (32P) to pancreatic tumours – • OncoSil device is now approved for sale in over 34 countries via CE Mark Commercialising For personal use only • Commercial ram
Slide 6: Executive Summary: Significant recent achievements
Executive Summary Received MDR approval and UKCA Certificate which includes the removal of all existing post-market restrictions in Europe and The UK (OSPREY registry) – reducing hospital customers friction and accelerating adoption 100% Recruitment achieved in landmark PANCOSIL study (a groundb
Slide 7: Pancreatic Cancer Prognosis has Remained Unchanged for Years
Pancreatic Cancer Prognosis has Remained Unchanged for 40 Years1 Changes in survival, 1971-72 to 2010-11 0% 25% 50% 75% 100% For personal use only All Cancers Incidence Survival rates are very poor: Testis Malignant Melanoma • 8.5 months overall median survival Prostate Hodgkin Lymphoma • <12% reach
Slide 8: Pancreatic Cancer Stage at Diagnosis
Pancreatic Cancer Stage at Diagnosis Surgical resection remains the only potentially curative treatment for pancreatic cancer1 RESECTABLE LOCALLY ADVANCED METASTATIC For personal use only % of patients at diagnosis 15% 30% 55% Surgical resection with Palliative therapies Palliative therapies curativ
Slide 9: OncoSil Device
OncoSil Device Driving increased resection rates, downstaging, survival benefits and quality of life For personal use only OncoSil is intended for the treatment of OncoSil is currently implanted Percutaneous delivery is transformational locally advanced unresectable pancreatic directly into a pancre
Slide 10: Site Training Update
Site Training Update Training New Sites to start OncoSilTM treatments For personal use only
Slide 11: Commercial Market Expansion
Commercial Market Expansion Existing Priority Markets Pancreatic Cancer Incidence Locally Advanced Pancreatic Target Market Market Opportunity ($USm) p.a.1 Cancer2 For personal use only UK 11,852 3,556 ~91 Spain 9,282 2,785 ~68 OncoSil device remains at the early- Italy 16,111 4,833 ~118 stage of co
Slide 12: Accelerating Commercialisation
Accelerating Commercialisation Compelling cost-benefit proposition with no direct competition • Average list price of ~€22k/~US$24k For personal use only Attractive Unit Economics • Gross Margin of 50% expected to increase to 65% driven by manufacturing productivity and targeting >75% device margins
Slide 13: Enhancing Market Access
Enhancing Market Access Program Description Key Milestones Commercial Impact For personal use only • Discussions remain ongoing and constructive with Bile Duct Cancer (Distal Chalingiocarcinoma - dCCA) Small addressable market however a US FDA Bile Duct For approval by US FDA under Human Device supp
Slide 14: Upcoming Milestones
Upcoming Milestones Significant commercial catalysts over the next 18 months Label expanded to include Label expansion Launch in SE Asia For personal use only Completion of Percutaneous Delivery with additional countries PANCOSIL study chemotherapy - FOLFIRINOX TGA Submission TGA Approval anticipate
Slide 15: Leadership Team
For personal use only Leadership Team
Slide 16: Experienced Board and Management
Experienced Board and Management Depth in Nuclear Medicine Commercialisation For personal use only Douglas Dr Thomas Lel Cubbin Duthy Smits Non-executive Non-executive Non-executive Chairman Director Director 30+ years’ biopharmaceutical 20+ years of experience across Award-winning entrepreneur, exp
Slide 17: Nigel Lange, CEO & Managing Director
For personal use only Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com Learn more about OncoSil Medical: • Website • ASX announcements • LinkedIn
OncoSil Medical — Investor Presentation (August 2025) on 6ix